New stroke treatment aims to bust clots directly in the brain

NCT ID NCT07668323

Not yet recruiting Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether giving clot-busting drugs directly into the blocked brain artery (intra-arterial thrombolysis) helps people recover better from a medium-vessel stroke. About 306 adults aged 18-80 with acute stroke will be randomly assigned to receive either the drug plus standard care or standard care alone. The main goal is to see if more people achieve functional independence (able to carry out daily activities) 90 days after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: clot-busting drugs (alteplase or tenecteplase)
What this could lead to: If it works, this could offer a new treatment option for people with medium-vessel stroke, potentially improving recovery and reducing disability.
What could go wrong: This is an early-stage trial with only 306 participants, so results may not apply to everyone. There is a risk of bleeding or other complications from the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ISCHEMIC STROKE, ACUTE MEDIUM VESSEL OCCLUSION

Contacts and locations

Locations

the First Affiliated Hospital with Nanjing Medical University

Nanjing, Jiangsu, 210000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.